Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...